These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26527653)

  • 1. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
    Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
    Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
    Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
    Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
    Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
    Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
    Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models of Mdm2 and Mdm4 and their clinical implications.
    Xiong S
    Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination.
    Wu H; Zeinab RA; Flores ER; Leng RP
    Mol Cancer Res; 2011 Dec; 9(12):1780-90. PubMed ID: 21994467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
    Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
    Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress.
    Lehman JA; Waning DL; Batuello CN; Cipriano R; Kadakia MP; Mayo LD
    J Biol Chem; 2011 Oct; 286(42):36631-40. PubMed ID: 21873427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
    Grier JD; Xiong S; Elizondo-Fraire AC; Parant JM; Lozano G
    Mol Cell Biol; 2006 Jan; 26(1):192-8. PubMed ID: 16354690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
    Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
    J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.
    Pant V; Xiong S; Iwakuma T; Quintás-Cardama A; Lozano G
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11995-2000. PubMed ID: 21730132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of p53 and its homolog p73 by protoporphyrin IX.
    Sznarkowska A; Maleńczyk K; Kadziński L; Bielawski KP; Banecki B; Zawacka-Pankau J
    FEBS Lett; 2011 Jan; 585(1):255-60. PubMed ID: 21146529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
    Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
    Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible role of p73 on the modulation of p53 level through MDM2.
    Wang XQ; Ongkeko WM; Lau AW; Leung KM; Poon RY
    Cancer Res; 2001 Feb; 61(4):1598-603. PubMed ID: 11245471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of p73 in malignancy: tumor suppressor or oncogene?
    Stiewe T; Pützer BM
    Cell Death Differ; 2002 Mar; 9(3):237-45. PubMed ID: 11859406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdm2 and Mdm4 loss regulates distinct p53 activities.
    Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
    Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
    Sampath D; Calin GA; Puduvalli VK; Gopisetty G; Taccioli C; Liu CG; Ewald B; Liu C; Keating MJ; Plunkett W
    Blood; 2009 Apr; 113(16):3744-53. PubMed ID: 19096009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
    Jung YS; Qian Y; Chen X
    J Biol Chem; 2011 Oct; 286(41):35388-35395. PubMed ID: 21852228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.